Randomized Trial of Radiotherapy Versus Concurrent Chemoradiotherapy Followed by Adjuvant Chemotherapy in Patients With American Joint Committee on Cancer/International Union Against Cancer Stage III and IV Nasopharyngeal Cancer of the Endemic Variety
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Purpose: The Intergroup 00-99 Trial for nasopharyngeal cancer (NPC) showed a benefit of adding chemotherapy to radiotherapy. However, there were controversies regarding the applicability of the results to patients in endemic regions. This study aims to confirm the findings of the 00-99 Trial and its applicability to patients with endemic NPC. Patients and Methods: Between September 1997 and May 2003, 221 patients were randomly assigned to receive radiotherapy (RT) alone (n = 110) or chemoradiotherapy (CRT; n = 111). Patients in both arms received 70 Gy in 7 weeks using standard RT portals and techniques. Patients on CRT received concurrent cisplatin (25 mg/m 2 on days 1 to 4) on weeks 1, 4, and 7 of RT and adjuvant cisplatin (20 mg/m 2 on days 1 to 4) and fluorouracil (1,000 mg/m 2 on days 1 to 4) every 4 weeks (weeks 11, 15, and 19) for three cycles after completion of RT. All patients were analyzed by intent-to-treat analysis. The median follow-up time was 3.2 years. Results: Distant metastasis occurred in 38 patients on RT alone and 18 patients on CRT. The difference in 2-year cumulative incidence was 17% (95% CI, 14% to 20%; P = .0029). The hazard ratio (HR) for disease-free survival was 0.57 (95% CI, 0.38 to 0.87; P = .0093). The 2- and 3-year overall survival (OS) rates were 78% and 85% and 65% and 80% for RT alone and CRT, respectively. The HR for OS was 0.51 (95% CI, 0.31 to 0.81; P = .0061). Conclusion: This report confirms the findings of the Intergroup 00-99 Trial and demonstrates its applicability to endemic NPC. This study also confirms that chemotherapy improves the distant metastasis control rate in NPC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
The Statistical Analysis of Failure Time Data.
Aitkin, M., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,877
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,960
Cooper, J. S., Pajak, T. F., Forastiere, A. A., Jacobs, J., Campbell, B. H., Saxman, S. B., Kish, J. A., Kim, H. E., Cmelak, A. J., Rotman, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032646 · Cited by 3,269
Bernier, J., Domenge, C., Ozsahin, M., Matuszewska, K., Lefèbvre, J.-L., Greiner, R. H., Giralt, J., Maingon, P., Rolland, F., Bolla, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032641 · Cited by 3,192
Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer
Forastiere, A. A., Goepfert, H., Maor, M., Pajak, T. F., Weber, R., Morrison, W., Glisson, B., Trotti, A., Ridge, J. A., Chao, C., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa031317 · Cited by 3,174
Morris, M., Eifel, P. J., Lu, J., Grigsby, P. W., Levenback, C., Stevens, R. E., Rotman, M., Gershenson, D. M., & Mutch, D. G. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904153401501 · Cited by 2,299
Al-Sarraf, M., LeBlanc, M., Giri, P. G., Fu, K. K., Cooper, J., Vuong, T., Forastiere, A. A., Adams, G., Sakr, W. A., Schuller, D. E., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.4.1310 · Cited by 2,222
Cited by
Chen, Y.-P., Chan, A. T. C., Le, Q.-T., Blanchard, P., Sun, Y., & Ma, J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30956-0 · Cited by 3,077
Chua, M. L. K., Wee, J. T. S., Hui, E. P., & Chan, A. T. C. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00055-0 · Cited by 1,236
Self-citationManagement of Nasopharyngeal Carcinoma: Current Practice and Future Perspective
Lee, A. W. M., Ma, B. B. Y., Ng, W. T., & Chan, A. T. C. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.9347 · Cited by 796
Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis
Blanchard, P., Lee, A., Marguet, S., Leclercq, J., Ng, W. T., Ma, J., Chan, A. T. C., Huang, P.-Y., Benhamou, E., Zhu, G., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70126-9 · Cited by 755
Lee, N., Harris, J., Garden, A. S., Straube, W., Glisson, B., Xia, P., Bosch, W., Morrison, W. H., Quivey, J., Thorstad, W., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.9109 · Cited by 706
Chen, L., Hu, C.-S., Chen, X.-Z., Hu, G.-Q., Cheng, Z.-B., Sun, Y., Li, W.-X., Chen, Y.-Y., Xie, F.-Y., Liang, S.-B., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70320-5 · Cited by 558
Nasopharyngeal carcinoma: an evolving paradigm
Wong, K. C. W., Hui, E. P., Lo, K.-W., Lam, W. K. J., Johnson, D., Li, L., Tao, Q., Chan, K. C. A., To, K.-F., King, A. D., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00524-x · Cited by 546
Pfister, D. G., Ang, K.-K., Brizel, D. M., Burtness, B. A., Cmelak, A. J., Colevas, A. D., Dunphy, F., Eisele, D. W., Gilbert, J., Gillison, M. L., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0053 · Cited by 413
Tang, L., Chen, Y., Chen, C., Chen, M., Chen, N., Chen, X., Du, X., Fang, W., Feng, M., Gao, J., et al. (2021) · Cancer Communications · doi:10.1002/cac2.12218 · Cited by 413
Chen, Y.-P., Ismaila, N., Chua, M. L. K., Colevas, A. D., Haddad, R., Huang, S. H., Wee, J. T. S., Whitley, A. C., Yi, J.-L., Yom, S. S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03237 · Cited by 390
Self-citationLee, N. Y., Zhang, Q., Pfister, D. G., Kim, J., Garden, A. S., Mechalakos, J., Hu, K., Le, Q. T., Colevas, A. D., Glisson, B. S., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70303-5 · Cited by 359
Ribassin-Majed, L., Marguet, S., Lee, A. W. M., Ng, W. T., Ma, J., Chan, A. T. C., Huang, P.-Y., Zhu, G., Chua, D. T. T., Chen, Y., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.4119 · Cited by 352
Chen, Q.-Y., Wen, Y.-F., Guo, L., Liu, H., Huang, P.-Y., Mo, H.-Y., Li, N.-W., Xiang, Y.-Q., Luo, D.-H., Qiu, F., et al. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr432 · Cited by 339
Lee, A. W. M., Tung, S. Y., Chua, D. T. T., Ngan, R. K. C., Chappell, R., Tung, R., Siu, L., Ng, W. T., Sze, W. K., Au, G. K. H., et al. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq258 · Cited by 318
Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments
Tao, Q., & Chan, A. T. C. (2007) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399407000312 · Cited by 312
Current Management of Nasopharyngeal Cancer
Lee, A. W. M., Lin, J. C., & Ng, W. T. (2012) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2012.03.008 · Cited by 294
Cao, S.-M., Yang, Q., Guo, L., Mai, H.-Q., Mo, H.-Y., Cao, K.-J., Qian, C.-N., Zhao, C., Xiang, Y.-Q., Zhang, X.-P., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.039 · Cited by 279
Metadata
- Authors
- Wee, J., Tan, E. H., Tai, B. C., Wong, H. B., Leong, S. S., Tan, T., Chua, E. T., Yang, E., Lee, K. M., Fong, K. W., Tan, H. S. K., Lee, K. S., Loong, S., Sethi, V., Chua, E. J., & Machin, D.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-09-20
- Volume
- 23
- Issue
- 27
- Pages
- 6730-6738
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2158776902
- Cited by
- 650
- References
- 27
- FWCI
- 23.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.